Cipla has signed a non-exclusive Patent License agreement with Takeda Pharmaceutical company Ltd. for ‘Vonoprazan’ for India Market for treating acid-related illnesses among patients.

This deal is meant to commercialise the drug in India under Cipla’s own trademark brands.

Vonoprozan (oral tablets) is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of related disorders - Gastroesophageal Reflux Disease (GERD).

Vonoprozan will help in treating disorders such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro- oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication.

Achin Gupta, CEO – One India Business, Cipla Ltd., said, “Bringing new and advanced therapies to the Indian market has always been a key area of focus for us. We believe this partnership will not only address a significant medical need, but also strive to provide a better quality of life for patients.”